Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment
Description
CONCLUSION: Eculizumab was used effectively and safely in Turkish AQP4-IgG+NMOSD patients with high disease activity. Disease reactivation and relapse may occur after discontinuation of eculizumab treatment in patients with a long-term stable course
